Compare SKY & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKY | SRRK |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 5.2B |
| IPO Year | 1994 | 2018 |
| Metric | SKY | SRRK |
|---|---|---|
| Price | $91.83 | $46.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 18 |
| Target Price | ★ $101.83 | $70.44 |
| AVG Volume (30 Days) | 680.3K | ★ 1.6M |
| Earning Date | 11-03-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.02 | N/A |
| EPS | ★ 1.86 | N/A |
| Revenue | ★ $2,663,639,000.00 | N/A |
| Revenue This Year | $4.80 | N/A |
| Revenue Next Year | $7.49 | $2,397.26 |
| P/E Ratio | $51.70 | ★ N/A |
| Revenue Growth | ★ 7.26 | N/A |
| 52 Week Low | $63.87 | $28.79 |
| 52 Week High | $99.17 | $61.76 |
| Indicator | SKY | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 61.88 | 60.01 |
| Support Level | $89.31 | $45.82 |
| Resistance Level | $97.54 | $48.66 |
| Average True Range (ATR) | 3.44 | 1.82 |
| MACD | 1.89 | 0.87 |
| Stochastic Oscillator | 76.29 | 88.90 |
Champion Homes Inc is a factory-built housing company in North America. The company is well positioned with an portfolio of manufactured and modular homes, ADUs, park-models and modular buildings for the single-family, multi-family, and other hospitality sectors. In addition to its core home building business, the company provides construction services to install and set-up factory-built homes, operates a factory-direct retail business across the United States, and operates Star Fleet Trucking, providing transportation services to the manufactured housing and other industries from several locations across the US. The Company has two reportable segment U.S. Factory-built Housing and Canadian Factory-built Housing. The majority of the revenue is generated from U.S. Factory-built Housing.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.